Care Step Pathway – Neuropathy (motor or sensory nerve impairment or damage)

Assessment

Look:

- Does the patient appear weak?
- Does the patient appear uncomfortable?
- Altered ambulation or general movement?
- Does the patient have loss of fine motor control?
- If muscular weakness is present, any respiratory difficulties apparent?

Listen:

- Does the patient report weakness (unilateral or bilateral)?
- Does the patient report new or worsened pain, numbness, or tingling?
- Does the patient report difficulty walking or holding

Recognize:

- Motor deficits
- Sensory deficits
- Mental status changes
- Paresthesias
- Laboratory values
- Past history of toxicities with other therapies
- Does the patient have diabetes mellitus?
- Are there neurologic signs and symptoms?
- Results of prior imaging
 - o Metastases to spinal cord
 - o Other metastases that may cause symptoms

Grading Toxicity

Grade 1 (Mild)

Peripheral Motor:

- Asymptomatic; clinical or diagnostic observations only
- No intervention indicated

Peripheral Sensory:

Asymptomatic; loss of deep tendon reflexes

Grade 2 (Moderate)

Peripheral Motor:

Moderate symptoms; limiting instrumental

Peripheral Sensory:

Moderate symptoms; limiting instrumental

Grade 3 (Severe)

Peripheral Motor:

Severe symptoms; limiting self-care ADLs; requires assistive devices

Peripheral Sensory:

Severe symptoms; limiting self-care **ADLs**

Grade 4 (Potentially Life-Threatening)

Life-threatening; urgent intervention indicated

Peripheral Sensory:

Life-threatening; urgent intervention indicated

Management

Overall Strategy:

- Screen for neuropathy causes: diabetes with HbA1C, vit B12, folates, TSH, and HIV
- Rule out infectious, noninfectious, disease-related etiologies (medications, metabolic/endocrine disorders, environmental exposures, vascular or autoimmune, trauma, progressive disease)
- For grade 2 or higher consider steroids* (0.5-1 mg/kg/day prednisone or equivalent) to be used
- Consider holding ICI therapy for mild neuropathy
- Hold ICI therapy for moderate-to-severe neuropathy
- Neurology consult
 - o Consideration of electromyelography and nerve conduction tests
 - o Immune globulin infusions (at the direction of neurology)
 - o Plasmapheresis (at the direction of neurology)
- Taper steroids* slowly over at least 4 weeks once symptoms improve
- If needed, obtain physical therapy or occupational therapy consult (for both functional assessment and evaluate safety of patient at home)
- Supportive medications for symptom management (e.g., gabapentin, pregabalin, or duloxetine)
 For any patient with severe weakness, ascending paralysis, diplopia, ptosis, difficulty breathing, consider admission to hospital with urgent neurology consultation

Implementation:

- Compare baseline assessment; grade & document neuropathy and etiology (diabetic, medication, vascular, chemotherapy)
- Early identification and evaluation of patient symptoms
- Early intervention with lab work and office visit if neuropathy symptoms suspected

*Administering Corticosteroids:

Corticosteroid taper instructions/calendar as a guide but not an absolute

- Taper should consider patient's current symptom profile
- Close follow-up in person or by phone, based on individual need and symptomatology
- Corticosteroids may cause indigestion; provide antacid therapy daily as gastric ulcer prevention while on corticosteroids (e.g., proton pump inhibitor or H2 blocker if prednisone dosage is >20
- Review corticosteroid medication side effects: mood changes (angry, reactive, hyperaware, euphoric, manic), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down and report them (taper may need to be adjusted)

Long-term high-dose corticosteroids:

- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose M/W/F; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- If extended corticosteroid use, risk for osteoporosis; initiate calcium and vitamin D supplements
- Patients with asthma or who smoke may have decreased sensitivity to corticosteroids

RED FLAGS:

- Ascending paralysis, difficulty breathing (Guillain–Barré syndrome)
- Ptosis, diplopia, muscle weakness, difficulty with breathing, weak (myasthenia gravis)
- Pain, numbness, and asymmetrical weakness consistent with a vasculitis syndrome

